Search hospitals > Minnesota > Saint Paul
Saint John's Hospital - Healtheast
Claim this profileSaint Paul, Minnesota 55109
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Ovarian Cancer
339 reported clinical trials
12 medical researchers
Summary
Saint John's Hospital - Healtheast is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Ovarian Cancer and other specialties. Saint John's Hospital - Healtheast is involved with conducting 339 clinical trials across 430 conditions. There are 12 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park8 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
104 reported clinical trials
167 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital6 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
61 reported clinical trials
110 drugs studied
Yan JiRegions Hospital2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
32 reported clinical trials
78 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park6 years of reported clinical research
Studies Cancer
Studies Relapse
14 reported clinical trials
19 drugs studied
Clinical Trials running at Saint John's Hospital - Healtheast
Lung Cancer
Prostate Cancer
Bladder Cancer
Breast Cancer
Ovarian Cancer
Cancer
Breast cancer
Colorectal Cancer
Pancreatic Cancer
Esophageal cancer
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint John's Hospital - Healtheast?
Saint John's Hospital - Healtheast is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Ovarian Cancer and other specialties. Saint John's Hospital - Healtheast is involved with conducting 339 clinical trials across 430 conditions. There are 12 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Saint John's Hospital - Healtheast located?
St. John's Hospital, also known as HealthEast Hospital, is located at 1575 Beam Ave, Maplewood, MN 55109. Directions include taking I-94 E to exit 238A for US-61 N towards Maplewood, then continuing on US-61 N to Beam Ave.
Who should I call to ask about financial aid or insurance network?
**Saint John's Hospital - Healtheast Contact Information**
**Financial Assistance:**
- **Phone:** 307.739.4848
- **Email:** patientassistance@stjohns.health
- **Address:** St. John's Health, 555 E. Broadway, Jackson, WY 83001
Patients seeking financial assistance should contact the Patient Assistance Team at 307.739.4848 or via email at patientassistance@stjohns.health. They must provide proof of income for eligibility assessment and can inquire about payment plans for various charges.
**Insurance:**
- **Phone:** (914) 964-4664
- **Address:** St. John's Riverside Hospital, 2 Park Avenue 4th floor, Yonkers, New York 10703
For insurance inquiries or assistance, including eligibility for the Health Solution program for uninsured patients, contact (914) 964-4664 or visit the Financial Counselor at St. John's Riverside Hospital.
What insurance does Saint John's Hospital - Healtheast accept?
Saint John's Hospital - Healtheast accepts a wide range of insurance plans, including but not limited to Aetna, Blue Cross Blue Shield, Cigna, Medicare, United Healthcare, and Medicaid from Colorado and Idaho. They also accept insurance through various programs such as Cal Mediconnect, HEALTH NET DUAL ELIGIBLE, OSCAR HEALTH PLAN, and ANTHEM BLUE CROSS HMO-PPO. Coverage extends to specific plans like BLUE SHIELD COVERED CALIFORNIA SHOP, AETNA HMO-PPO, and UNITED HEALTHCARE HMO - PPO, among others.
What awards or recognition has Saint John's Hospital - Healtheast received?
St. John's Hospital, located in Saint Paul, Minnesota, is recognized as one of America's Best Hospitals by U.S. News & World Report in 2009-2010, ranking in the Top 50 for Urology. It has been awarded the Innovation of the Year in Patient Care by the Minnesota Hospital Association in 2009. Additionally, it has received accolades from the American Heart Association and American Stroke Association for exceptional treatment of heart and stroke patients.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.